Background
Methods
Study population
Sample collection, HIV-1, HBsAg detection and HIV-1 and HBV Plasma Viral load quantification
DNA extraction and APOBEC3G genotyping
HBV genotyping
Ethical considerations
Statistical analysis
Results
Clinical and biological features
HIV(+)/HBV(+) n = 85 | HIV(+) (n = 35) | HBV(+) (n = 65) | HIV(−)/HBV(−) n = 239 | |
---|---|---|---|---|
Detectable HBV Viral Load | 35 | – | 20 | – |
Mean HIV-1 Viral Loads | 65,963.68 +/−20,2480 | 6,758.13+/− 30368.61 | – | – |
Mean CD4 counts | 423.45 +/−300.33 | 375.12 +/− 277,20 | N/A | N/A |
HBV genotypes E n (%) | 100 | – | 100 | – |
Alleles and Genotypes frequencies
HIV (+) versus HIV(−)/HBV(−) | HBV(+) versus HIV(−)/HBV(−) | HIV(+)/HBV(+) versus HIV(−)/HBV(−) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Polymorphisms | HIV(+) | HBV(+) | HIV(+)/HBV(+) | HIV(−)/HBV(−) | OR | 95 % CI | p-Value | OR | 95 % CI | p-Value | OR | 95 % CI | p-Value |
(n = 35) | (n = 65) | (n = 85) | (n = 239) | ||||||||||
rs6001417 | |||||||||||||
CC, n (%) | 10 (28.57) | 15 (0.23) | 26 (30.59) | 64 (0.27) | 1.09 | 0.5–2.4 | 0.84 | 0.82 | 0.43–1.56 | 0.63 | 1.2 | 0.7–2.07 | 0.57 |
CG, n (%) | 17 (48.57) | 40 (0.61) | 48 (56.47) | 114 (0.48) | 1.03 | 0.51–2.1 | 1 | 1.75 | 1.01–3.07 |
0.05
| 1.47 | 0.89–2.42 | 0.13 |
GG, n (%) | 8 (22.86) | 10 (0.15) | 11 (12.94) | 61 (0.25) | 0.415 | 0.37–2 | 0.84 | 0.415 | 0.37–2 | 0.84 | 0.415 | 0.207–0.83 |
0.02
|
G vs C, n (%) | 33 (0.94) | 60 (.92) | 35 (0.41) | 236 (0.99) | 0.9 | 0.55–1.51 | 0.8 | 0.82 | 0.55–1.2 | 0.32 | 0.759 | 0.5–1.06 | 0.06 |
HWE | 0.74 | 0.16 | 0.20 | 0.38 | – | – | – | – | – | – | – | – | – |
rs8177832 | |||||||||||||
AA. n (%) | 10 (28.57) | 15 (0.23) | 27 (31.76) | 69 (28.87) | 0.98 | 0.45–2.16 | 1 | 0.74 | 0.39–1.4 | 0.43 | 1.15 | 0.67–1.96 | 0.7 |
AG. n (%) | 18 (0.51) | 40 (0.61) | 45 (52.94) | 111 (0.46) | 1.22 | 0.60–2.48 | 0.59 | 1.84 | 1.05–3.23 |
0.04
| 1.34 | 0.82–2.2 | 0.26 |
GG. n (%) | 7(0.2) | 10 (0.15) | 13 (15.30) | 59 (0.25) | 0.76 | 0.32–1.84 | 0.67 | 0.55 | 0.26–1.15 | 0.13 | 0.53 | 0.28–1.02 | 0.07 |
G vs A. n (%) | 32 (0.91) | 60 (0.92) | 36 (42.35) | 229 (0.96) | 0.9 | 0.55–1.51 | 0.8 | 0.82 | 0.55–1.2 | 0.32 | 0.77 | 0.54–1.09 | 0.15 |
HWE | 0.98 | 0.16 | 0.59 | 0.21 | – | – | – | – | – | – | – | – | – |
rs35228531 | |||||||||||||
CC. n (%) | 18 (0.51) | 18 (0.51) | 40 (47.05) | 84 (35.15) | 1.95 | 0.96–4 | 0.09 | 1.15 | 0.65–2.03 | 0.66 | 1.64 | 0.99–2.71 | 0.07 |
CT. n (%) | 15 (0.43) | 15 (0.43) | 38 (44.70) | 113 (0.47) | 0.84 | 0.4–1.71 | 0.17 | 0.95 | 0.55–1.65 | 0.89 | 0.93 | 0.57–1.53 | 0.80 |
TT. n (%) | 2 (0.06) | 2 (0.06) | 7 (8.25) | 42 (0.17) | 0.28 | 0.06–1.23 | 0.09 | 0.85 | 0.40–1.80 | 0.85 | 0.4 | 0.17–0.9 |
0.04
|
T vs C. n (%) | 19 (0.54) | 19 (0.54) | 25 (29.88) | 197 (0.82) | 0.53 | 0.3–0.93 |
0.03
| 0.89 | 0.6–1.33 | 0.615 | 0.61 | 0.42–0.90 |
0.01
|
HWE | 0.88 | 0.98 | 0.86 | 0.55 | – | – | – | – | – | – | – | – | – |
Markers | Models | OR | 95 % CI | p-Value |
---|---|---|---|---|
rs6001417 | C/C (referent). C/G. G/G. additive | 2.4 | 1.21–4.7 |
0.01
|
C/C vs. C/G & G/G. dominant | 1.20 | 0.7–2.07 | 0.5 | |
G/G vs. G/G&G/G. recessive | 0.4 | 0.2–0.83 |
0.01
| |
rs8177832 | A/A (referent). A/G. G/G additive | 1.88 | 0.99–3.57 | 0.06 |
A/A vs. A/G &G//G. dominant | 1.15 | 0.67–1.96 | 0.62 | |
G/G vs. A/A &A/G. recessive | 0.53 | 0.27–1.017 | 0.07 | |
rs35228531 | C/C (referent). C/T. T/T. additive | 2.66 | 1.16–6.07 |
0.02
|
C/C vs. C/T & T/T. dominant | 1.64 | 0.99–2.71 | 0.07 | |
T/T vs. C/C & C/T. recessive | 0.4 | 0.17–0.92 |
0.04
|
Haplotypes in cases and controls
Haplotype | HIV(+)/HBV(+) | HIV(−)/HBV(−) | OR | CI | p-Value |
---|---|---|---|---|---|
CAC | 0.54 | 0.51 | 1.27 | 0.77–2.1 | 0.38 |
GGC | 0.11 | 0.11 | 1.45 | 0.62–3.73 | 0.37 |
GGT | 0.27 | 0.31 | 0.57 | 0.33–0.99 |
0.05
|
CGC | 0.04 | 0.02 | 2.15 | 0.47–9.81 | 0.40 |
GAT | 0.02 | 0.02 | 1.41 | 0.25–7.87 | 0.65 |
GAC | 0.01 | 0.01 | 0.94 | 0.1–9.1 | 1 |